These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37440791)

  • 1. Home pregnancy tests for iPLEDGE: ethically dealing with potential falsifications.
    Schwartzman G; Flowers H; Grant-Kels JM
    Int J Womens Dermatol; 2023 Oct; 9(3):e093. PubMed ID: 37440791
    [No Abstract]   [Full Text] [Related]  

  • 2. Falsification of at-home isotretinoin pregnancy testing during the COVID-19 pandemic: A case series and proposal of mitigation strategies.
    Johnson H; Ranum A; Mansh M; Farah RS; Pearson DR
    JAAD Case Rep; 2022 Oct; 28():49-53. PubMed ID: 35971550
    [No Abstract]   [Full Text] [Related]  

  • 3. iPLEDGE Must Abstain from Abstinence.
    Lowery K; Rosen T; Malek J
    J Clin Aesthet Dermatol; 2020 Jun; 13(6):54-56. PubMed ID: 32884622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US Food and Drug Administration Reports of Pregnancy and Pregnancy-Related Adverse Events Associated With Isotretinoin.
    Tkachenko E; Singer S; Sharma P; Barbieri J; Mostaghimi A
    JAMA Dermatol; 2019 Oct; 155(10):1175-1179. PubMed ID: 31314041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simplifying contraception requirements for iPLEDGE: A decision analysis.
    Barbieri JS; Roe AH; Mostaghimi A
    J Am Acad Dermatol; 2020 Jul; 83(1):104-108. PubMed ID: 32068040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administrative Burden of iPLEDGE Deters Isotretinoin Prescriptions: Results From a Survey of Dermatologists.
    Lee G; Wolf JR; Somers KE
    Cutis; 2022 Jul; 110(1):44-47. PubMed ID: 36179224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in isotretinoin start, interruption, and early termination across race and sex in the iPLEDGE era.
    Charrow A; Xia FD; Lu J; Waul M; Joyce C; Mostaghimi A
    PLoS One; 2019; 14(3):e0210445. PubMed ID: 30913210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circumventing iPLEDGE: Circumventing ethical responsibility?
    Lee KC; Bercovitch L
    J Am Acad Dermatol; 2017 Dec; 77(6):1185-1187. PubMed ID: 29132856
    [No Abstract]   [Full Text] [Related]  

  • 9. COVID-19 Pandemic Leading to the Accelerated Development of a Virtual Health Model for Isotretinoin.
    Kane S; Admani S
    J Dermatol Nurses Assoc; 2021; 13(1):54-57. PubMed ID: 34191969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Access in Restrictive Risk Management Programs: The Case of iPLEDGE.
    Kerr KW; Wosinska ME
    Ther Innov Regul Sci; 2017 Jan; 51(1):16-23. PubMed ID: 30235995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant use of isotretinoin and contraceptives before and after iPledge in the United States.
    Pinheiro SP; Kang EM; Kim CY; Governale LA; Zhou EH; Hammad TA
    Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1251-7. PubMed ID: 23913625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Call for Gender Identity Data Collection in iPLEDGE and Increasing the Number of Isotretinoin Prescribers Among Transgender Health Providers.
    Singer S; Keuroghlian AS
    LGBT Health; 2020 Jul; 7(5):216-219. PubMed ID: 32456537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case.
    Honein MA; Lindstrom JA; Kweder SL
    Drug Saf; 2007; 30(1):5-15. PubMed ID: 17194167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the iPLEDGE program on isotretinoin fetal exposure in an integrated health care system.
    Shin J; Cheetham TC; Wong L; Niu F; Kass E; Yoshinaga MA; Sorel M; McCombs JS; Sidney S
    J Am Acad Dermatol; 2011 Dec; 65(6):1117-25. PubMed ID: 21565419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ignoring the elephant in the room-overregulated isotretinoin and unregulated dietary supplements in the United States.
    Zamil DH; Paidisetty PS; Wang LK
    Proc (Bayl Univ Med Cent); 2022; 35(6):892-893. PubMed ID: 36304632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPLEDGE Weaknesses: Is It Time to Address the Flaws?
    Cyrulnik AA; Gewirtzman AJ; Paz KB; Glick JB; Anam AK; Carrasco DA; Shalita AR; Cohen SR
    J Drugs Dermatol; 2016 Jan; 15(1):97-102. PubMed ID: 26741387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of iPLEDGE: We pledge for more inclusive access to isotretinoin.
    Shah N; Kirkorian AY
    Pediatr Dermatol; 2021 Nov; 38 Suppl 2():183-184. PubMed ID: 34184311
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of oral vitamin A in acne management: a review.
    Cook MK; Perche PO; Feldman SR
    Dermatol Online J; 2022 Oct; 28(5):. PubMed ID: 36809126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Important controversies associated with isotretinoin therapy for acne.
    Wolverton SE; Harper JC
    Am J Clin Dermatol; 2013 Apr; 14(2):71-6. PubMed ID: 23559397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Women's experiences with isotretinoin risk reduction counseling.
    Werner CA; Papic MJ; Ferris LK; Lee JK; Borrero S; Prevost N; Schwarz EB
    JAMA Dermatol; 2014 Apr; 150(4):366-71. PubMed ID: 24258663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.